Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of December 29, 2019.
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of December 29, 2019.
Chembio Anticipates FDA Approval of DPP HIV-Syphilis Test During Q1 2020
Chembio Diagnostics, Inc. has provided an update on its premarket approval application submission to the FDA for the DPP HIV-Syphilis System, which includes the DPP HIV-Syphilis test and DPP Micro Reader. The firm anticipates FDA approval of the DPP HIV-Syphilis System in the first of 2020.
The DPP HIV-Syphilis System is a 15-minute, single use screening test for the detection of antibodies to HIV types 1 and 2 as well as Treponema pallidum, the bacteria which causes syphilis. The test uses a 10 microliter sample of fingerstick of whole blood, venous whole blood, or plasma. It is highly specific and sensitive, can be stored at room temperature, and has a shelf life of up to 24 months.
Read the full press release here.
Novan Announces Top-Line Efficacy Results From Phase 3 Trials of SB206 for Molluscum Contagiosum
Novan, Inc. has announced top-line efficacy results from its phase 3 B-SIMPLE program with SB206 for treatment of molluscum contagiosum. SB206 did not achieve statistical significance for the primary endpoint in B-SIMPLE1 or B-SIMPLE2, but several sensitivity analyses are supportive and consistent across studies in support of a possible path forward.
B-SIMPLE2 was statistically significant for prespecified sensitivity analyses, and the firm intends to use the results as a confirmatory trial for the New Drug Application Submission.
Both trials are ongoing and awaiting 24-week safety data.
Read the full press release here.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.